TECHNESCAN MAG3 Drug Patent Profile

Which patents cover Technescan Mag3, and what generic alternatives are available?

Technescan Mag3 is a drug marketed by Curium and is included in one NDA.

The generic ingredient in TECHNESCAN MAG3 is technetium tc-99m mertiatide kit. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the technetium tc-99m mertiatide kit profile page.

Summary for TECHNESCAN MAG3

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	21
What excipients (inactive ingredients) are in TECHNESCAN MAG3?	TECHNESCAN MAG3 excipients list
DailyMed Link:	TECHNESCAN MAG3 at DailyMed

US Patents and Regulatory Information for TECHNESCAN MAG3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	TECHNESCAN MAG3	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	019882-001	Jun 15, 1990	AP	RX	Yes	Yes

Expired US Patents for TECHNESCAN MAG3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Curium	TECHNESCAN MAG3	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	019882-001	Jun 15, 1990	5,573,748

International Patents for TECHNESCAN MAG3

See the table below for patents covering TECHNESCAN MAG3 around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H0769935	KIT CONTAINING RADIOACTIVE TECNETIUM LABEL AND USED FOR MEASUREMENT OF KIDNEY FUNCTION
Japan	H0749406
Canada	1292084	CHELATES MARQUES AU TECHNETIUM RADIOACTIF POUVANT ETRE UTILISES DANS LES ANALYSES DE LA FONCTION RENALE (RADIOLABELED TECHNETIUM CHELATES FOR USE IN RENAL FUNCTION DETERMINATIONS)
Japan	H05208986	RADIOACTIVITY-LABELLING TECHNETIUM CHELATE COMPOUND FOR MEASURING KIDNEY FUNCTION
Canada	1317066	LIGAND PERMETTANT DE FORMER DES PRODUITS DE CHELATION MARQUES AU TECHNETIUM POUVANT ETRE UTILISES DANS LES TESTS DE LA FONCTION RENALE (LIGAND FOR FORMING RADIOLABELED TECHNETIUM CHELATES FOR USE IN RENAL FUNCTION DETERMINATIONS)
Austria	60714

Supplementary Protection Certificates for TECHNESCAN MAG3

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

TECHNESCAN MAG3 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Technescan MAG3

Introduction

Technescan MAG3, also known as technetium-99m mercaptoacetyltriglycine (MAG3), is a radiopharmaceutical widely used in renal imaging to diagnose and monitor various kidney disorders. This article delves into the market dynamics and financial trajectory of Technescan MAG3, highlighting its usage, pricing, and cost implications.

Market Overview

Technescan MAG3 is a key player in the renal imaging market, particularly due to its favorable physical and dosimetric characteristics. It has largely replaced iodide-131 Hippuran for studying renal function, especially tubular secretion physiology[4].

Usage and Applications

Renal Imaging

Technescan MAG3 is primarily used for renal scintigraphy and clearance measurements. It is preferred for its high tubular excretion rate, which allows for accurate assessment of renal function, especially in patients with renal insufficiency[2][4].

Diagnostic Advantages

The radiopharmaceutical offers several diagnostic advantages, including good quality images even in patients with poor renal function. It is also useful in detecting renal artery stenosis and monitoring the effects of certain medications on renal function[4].

Pricing and Cost Structure

Historical Pricing Model

Traditionally, Curium, the manufacturer of Technescan MAG3, used a pay-per-dose model where nuclear pharmacies paid for each dose compounded and dispensed. However, this model was complex and required significant tracking and reporting efforts[1].

Revised Pricing Model

In 2019, Curium transitioned to a price-per-vial approach, simplifying the cost structure for customers. The average price per vial was set at approximately $625 for most U.S. customers. This change aimed to reduce the administrative burden on customers and provide a clearer picture of supply costs[1].

Financial Implications

Cost Savings

Studies have shown that the use of Technescan MAG3 can lead to significant cost savings, especially when compared to other radiopharmaceuticals like Tc-99m DTPA. For instance, reserving MAG3 for patients with impaired renal function can result in substantial annual cost savings for radiology departments. Cost savings were estimated to be around $17,319 to $35,180 annually, depending on the serum creatinine and estimated glomerular filtration rate (eGFR) thresholds[2].

Raw Material and Preparation Costs

The cost analysis includes raw material and preparation costs. The radiotracer costs are estimated based on both vendor list pricing and proprietary institutional pricing, which can vary. However, the overall trend indicates that MAG3 can be more cost-effective in certain clinical scenarios[2].

Market Dynamics

Competition

The market for renal imaging radiopharmaceuticals is competitive, with other agents like Tc-99m DTPA and iodide-131 Hippuran. However, Technescan MAG3's favorable characteristics, such as its high tubular excretion rate and low radiation dose, give it a competitive edge[4].

Regulatory Environment

The regulatory environment plays a crucial role in the market dynamics of Technescan MAG3. Changes in regulatory requirements or reimbursement policies can significantly impact the financial trajectory of the drug. For example, any changes in FDA approvals or Medicare reimbursement rates could affect the demand and pricing of the radiopharmaceutical.

Industry Trends

Technological Advancements

Advancements in nuclear medicine technology, such as improved imaging techniques and new radiopharmaceuticals, can influence the market for Technescan MAG3. However, its established position and clinical benefits make it a stable choice in the market.

Patient Demographics

The increasing prevalence of kidney diseases and the growing need for accurate renal function assessments drive the demand for Technescan MAG3. This trend is expected to continue, supporting the financial stability of the drug.

Expert Insights

"After careful review of our sales approach, we are making this change to simplify the tracking and reporting demands of our customers and provide them a clearer picture of their supply costs," said Dan Brague, Curium CEO, North America. This shift reflects the industry's move towards more streamlined and cost-effective solutions[1].

Financial Projections

Given the cost savings and the competitive advantages of Technescan MAG3, the financial trajectory for this radiopharmaceutical is positive. The simplified pricing model and the ongoing demand for accurate renal imaging are expected to support stable revenue streams.

Key Takeaways

• Pricing Model: Transition from pay-per-dose to price-per-vial simplifies cost structure and reduces administrative burden.
• Cost Savings: Significant annual cost savings can be achieved by reserving MAG3 for patients with impaired renal function.
• Market Position: Technescan MAG3 remains a preferred choice in renal imaging due to its favorable physical and dosimetric characteristics.
• Regulatory and Technological Trends: Continued regulatory support and technological advancements in nuclear medicine are crucial for the drug's financial trajectory.

FAQs

What is Technescan MAG3 used for?

Technescan MAG3 is used for renal imaging to diagnose and monitor various kidney disorders, particularly for assessing tubular function and renal morphology.

How has the pricing model for Technescan MAG3 changed?

The pricing model has transitioned from a pay-per-dose to a price-per-vial approach, simplifying the cost structure and reducing administrative burdens for customers.

What are the cost savings associated with using Technescan MAG3?

Using Technescan MAG3 can result in significant annual cost savings, ranging from $17,319 to $35,180, depending on the serum creatinine and eGFR thresholds.

How does Technescan MAG3 compare to other radiopharmaceuticals?

Technescan MAG3 has favorable energy and dosimetric characteristics, making it superior to other agents like Tc-99m DTPA and iodide-131 Hippuran for certain clinical scenarios.

What are the key factors influencing the market dynamics of Technescan MAG3?

The market dynamics are influenced by factors such as regulatory environment, technological advancements, patient demographics, and the competitive landscape in the renal imaging market.

Sources

1. Curium Announces Revised Pricing for Technescan MAG3 TM (kit for the preparation of technetium Tc 99m mertiatide) - Curium Pharma.
2. Technetium-99m mercaptoacetyltriglycine mag3 - Science.gov.
3. INFORMATION STATEMENT Mallinckrodt plc - Investor Relations.
4. Tc-99m MAG3 - Radiopaedia.org.
5. TechneScan MAG3 Kit for the Preparation of Technetium Tc 99m Mertiatide - Pharmacy CE, University of New Mexico.